Northern Tier Energy LP (NYSE:NTI) shares moved down -4.44% in last trading session and ended the day at $23.02. NTI Gross Margin is 11.90% and its has a return on assets of 28.20%. Northern Tier Energy LP (NYSE:NTI) quarterly performance is -1.02%.
Northern Tier Energy LP (Northern Tier) is a downstream energy limited partnership. The Company has refining, retail and logistics operations that serve the Petroleum Administration for Defense District II (PADD II) region of the United States.
Northern Tier Energy LP (NYSE:NTI) was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday, MarketBeat Ratings reports. The brokerage currently has a $28.33 price target on the stock. Vetr‘s price objective suggests a potential upside of 17.60% from the company’s current price.
Zafgen, Inc. (NASDAQ:ZFGN) ended the last trading day at $33.78. Company weekly volatility is calculated as 8.89% and price to cash ratio as 4.16. Zafgen, Inc. (NASDAQ:ZFGN) showed a weekly performance of -23.44%.
Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO, and is in Phase IIb stage of development for severe obesity in the general population.
Zafgen, Inc. (NASDAQ:ZFGN) announced the appointment of Robert Perez and Geoffrey McDonough, M.D., to its Board of Directors. Mr. Perez is the former Chief Executive Officer of Cubist Pharmaceuticals, and brings over 28 years of experience from various leadership and senior management positions in the life sciences industry.
Plug Power Inc. (NASDAQ:PLUG) ended the last trading day at $1.83. Company weekly volatility is calculated as 8.11% and price to cash ratio as 2.91. Plug Power Inc. (NASDAQ:PLUG) showed a weekly performance of -15.67%.
Plug Power Inc. is a provider of alternative energy technology focused on the design, development, commercialization and manufacture of hydrogen fuel cell systems used for the industrial off-road market and the stationary power market. The Company’s product line includes GenKey, GenDrive, GenFuel, GenCare and ReliOn. GenKey offers solutions to customers transitioning their material handling vehicles to fuel cell power.
Plug Power Inc. (NASDAQ:PLUG) said that, Gary Mittleman will serve as president and CEO of ReVivo Medical LLC. The company focuses on innovations of the plates used to hold vertebrae in place following spinal surgeries and has two patents pending.
Array BioPharma Inc. (NASDAQ:ARRY) shares moved down -3.04% in last trading session and ended the day at $4.78. ARRY Gross Margin is 14.50% and its has a return on assets of 5.30%. Array BioPharma Inc. (NASDAQ:ARRY) quarterly performance is -32.29%.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS).
Array BioPharma Inc. (NASDAQ:ARRY) reported that it had presented clinical trial results on the combination of two of its cancer-fighting drugs at the European Society of Medical Oncology’s annual European Cancer Conference in Vienna, Austria over the weekend, and that the results are encouraging.
EMC Corporation (NYSE:EMC) caters to the Technology space. It has a net profit margin of 10.00% and weekly performance is -2.65%. On the last day of trading company shares ended up at $23.51. EMC Corporation (NYSE:EMC) distance from 50-day simple moving average (SMA50) is -6.88%.
EMC Corporation (EMC) is a service provider to information technology (IT) operations to an as a service model (ITaaS). It develops, delivers and supports the IT industry’s range of information infrastructure and virtual infrastructure technologies, solutions and services.
EMC Corporation (NYSE:EMC) announced a cash dividend payment of $0.115 per share is scheduled to be paid on October 23, 2015. Shareholders who purchased EMC prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 6th quarter that EMC has paid the same dividend. At the current stock price of $23.78, the dividend yield is 1.93%.
Leave a Reply